PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm
暂无分享,去创建一个
Jing Wang | M. Konopleva | L. Medeiros | J. Khoury | C. Yin | N. Pemmaraju | V. Prieto | Xiaofeng Zheng | R. Nejati | P. Aung | Weina Chen | S. Loghavi | Narittee Sukswai | Zhenya Tang | C. Torres-Cabala
[1] S. Lantuejoul,et al. Programmed death ligand 1 immunohistochemistry in non-small cell lung carcinoma. , 2019, Journal of thoracic disease.
[2] M. Konopleva,et al. Tagraxofusp in Blastic Plasmacytoid Dendritic‐Cell Neoplasm , 2019, The New England journal of medicine.
[3] E. V. Van Allen,et al. Genomic correlates of response to immune checkpoint blockade , 2019, Nature Medicine.
[4] R. Hájek,et al. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma , 2018, Front. Immunol..
[5] J. Khoury. Blastic Plasmacytoid Dendritic Cell Neoplasm , 2018, Current Hematologic Malignancy Reports.
[6] N. Pemmaraju,et al. Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. , 2018, Leukemia research.
[7] J. Bergh,et al. Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations , 2018, Oncogene.
[8] T. Schumacher,et al. Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.
[9] M. Rai,et al. Blastic plasmacytoid dendritic cell neoplasm , 2018, Clinical case reports.
[10] A. Sharpe,et al. The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.
[11] D. Hawiger,et al. Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells. , 2018, Critical reviews in immunology.
[12] P. Hari,et al. Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study , 2017, British journal of haematology.
[13] R. Broaddus,et al. Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial , 2017, Clinical Cancer Research.
[14] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[15] J. Pyo,et al. Prognostic Role of PD-L1 in Malignant Solid Tumors: A Meta-Analysis , 2016, The International journal of biological markers.
[16] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[17] Jinming Yu,et al. PD-L1 expression in human cancers and its association with clinical outcomes , 2016, OncoTargets and therapy.
[18] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[19] Daniela Massi,et al. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. , 2016, Critical reviews in oncology/hematology.
[20] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[21] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[22] A. Waage,et al. PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy , 2015, PloS one.
[23] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[24] Jian Huang,et al. PD-L1 and Survival in Solid Tumors: A Meta-Analysis , 2015, PloS one.
[25] M. Millenson,et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. , 2015, The New England journal of medicine.
[26] W. Hwu,et al. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. , 2015, Discovery medicine.
[27] M. Konopleva,et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. , 2014, Blood.
[28] F. Stingo,et al. BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild‐type RAS , 2014, American journal of hematology.
[29] L. Jeffrey Medeiros,et al. TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow , 2013, American journal of hematology.
[30] S. Pileri,et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study , 2013, Haematologica.
[31] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[32] M. Angelopoulou,et al. Acute lymphoplasmacytoid dendritic cell (DC2) leukemia: results from the Hellenic Dendritic Cell Leukemia Study Group. , 2010, Leukemia research.
[33] L. Medeiros,et al. Cytogenetic findings in blastoid mantle cell lymphoma. , 2003, Human pathology.
[34] M. Teitell,et al. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. , 2003, Blood.
[35] M. Callanan,et al. CD4(+), CD56(+) DC2 acute leukemia is characterized by recurrent clonal chromosomal changes affecting 6 major targets: a study of 21 cases by the Groupe Français de Cytogénétique Hématologique. , 2002, Blood.
[36] J. Manning,et al. CD56+ TdT+ blastic natural killer cell tumor of the skin , 2002, Cancer.